MHE May 2026

Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the company is looking to bridge the gaps among all stakeholders in burgeoning cell and gene therapy category.

Shrank, a longtime member of the MHE editorial advisory board, discusses the mainstreaming of CAR-T therapy and still-unique aspects of gene therapy

Shrank is president and co-founder of cell and gene therapy (CGT) startup Aradigm, which is working with patients, payers, providers, and manufacturers to manage the cost and financial risk of expensive cell and gene therapy.

A compare-and-contrast list for the two FDA-approved oral GLP-1s, Foundayo (orforglipron) and oral Wegovy (semaglutide).

Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup company focused on managing the cost and delivery fo cell and gene therapy.

Hospital prices have risen faster than other healthcare prices, and some say consolidation into large health systems is to blame. Hospitals counter that they are price takers, not setters.

More people stop taking the glucagon-like peptide 1 (GLP-1) drugs for weight loss than is commonly recognized. Insurance coverage is patchy, but for those who do have it, some pharmacy benefit managers have launched programs designed to help keep people keep taking their GLP-1.